Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Very Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy for Prevention of Viral Infection after Allogeneic T Cell Depleted Stem Cell Transplantation

Pawel Muranski, MD, Sarah I Davies, Sawa Ito, MD, Eleftheria Koklanaris, RN, Jeanine Superata, RN, Quan Yu, Steven L Highfill, PhD, Marianna Sabatino, MD, David F. Stroncek, Minoo Battiwalla, MD, Austin John Barrett

Blood (2018) 132 (Supplement 1): 812.

https://doi.org/10.1182/blood-2018-99-119314

Published: 2018

Journal Articles

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Blood (2016) 128 (22): 2803.

https://doi.org/10.1182/blood.V128.22.2803.2803

Published: 2016

Journal Articles

Production of Anti-CD19 CAR T Cells for ZUMA-3 and -4: Phase 1/2 Multicenter Studies Evaluating KTE-C19 in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL)

Marianna Sabatino, MD, Kenny Choi, BS, Vijay Chiruvolu, PhD, Marc Better, PhD

Blood (2016) 128 (22): 1227.

https://doi.org/10.1182/blood.V128.22.1227.1227

Published: 2016

Journal Articles

Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy to Prevent Viral Reactivation in Recipients of Allogeneic T Cell Depleted Stem Cell Transplant

Pawel Muranski, MD, Greg Whitehill, BS, Debbie Draper, RN, Eleftheria Koklanaris, RN, Jeanine Superata, RN, Quan Yu, MS, Marianna Sabatino, MD, Steven L. Highfill, PhD, Hanh Khuu, MD, Sarah I Davies, Mark Chang, Upneet Chawla, BS, MD, Alexandros Spyridonidis, MD PhD, Gary Fahle, MT,SM, Sawa Ito, MD PhD, David Stroncek, MD, Minoo Battiwalla, MDMS, John Barrett, MD

Blood (2016) 128 (22): 979.

https://doi.org/10.1182/blood.V128.22.979.979

Published: 2016

Journal Articles

Generation of clinical-grade CD19-specific CAR-modified CD8 + memory stem cells for the treatment of human B-cell malignancies

Marianna Sabatino, Jinhui Hu, Michele Sommariva, Sanjivan Gautam, Vicki Fellowes, James D. Hocker, Sean Dougherty, Haiying Qin, Christopher A. Klebanoff, Terry J. Fry, Ronald E. Gress, James N. Kochenderfer, David F. Stroncek, Yun Ji, Luca Gattinoni

Blood (2016) 128 (4): 519–528.

https://doi.org/10.1182/blood-2015-11-683847

Published: 2016

Includes: Supplemental data

Journal Articles

Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells

David F. Stroncek, MD, Daniel W. Lee, III, MD, Jiaqiang Ren, MD PhD, Marianna Sabatino, MD, Hanh Khuu, MD, Melinda S. Merchant, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 383.

https://doi.org/10.1182/blood.V126.23.383.383

Published: 2015

Journal Articles

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation

Nirali N. Shah, Kristin Baird, Cynthia P. Delbrook, Thomas A. Fleisher, Mark E. Kohler, Shakuntala Rampertaap, Kimberly Lemberg, Carolyn K. Hurley, David E. Kleiner, Melinda S. Merchant, Stefania Pittaluga, Marianna Sabatino, David F. Stroncek, Alan S. Wayne, Hua Zhang, Terry J. Fry, Crystal L. Mackall

Blood (2015) 125 (5): 784–792.

https://doi.org/10.1182/blood-2014-07-592881

Published: 2015

Journal Articles

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

Daniel W. Lee, MD, Maryalice Stetler-Stevenson, MD PhD, Marianna Sabatino, MD, Constance Yuan, MD PhD, Terry J Fry, MD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, Hua Zhang, PhD, Ling Zhang, Nick Tschernia, BS, Yongzhi Cui, MD PhD, Steven Feldman, PhD, James N Kochenderfer, MD, Steven A. Rosenberg, MD, PhD, David F. Stroncek, MD, Alan S. Wayne, MD, Crystal L Mackall, MD

Blood (2014) 124 (21): 381.

https://doi.org/10.1182/blood.V124.21.381.381

Published: 2014

Journal Articles

CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation

Ankit Anand, MD, Prathima Anandi, MD, Jain A. Natasha, MD, Kit Lu, MD, Neil Dunavin, MD, Christopher S. Hourigan, MDPhD, Robert Q. Le, MDPhD, Puja D. Chokshi, MD, Sawa Ito, MD, David F. Stroncek, MD, Marianna Sabatino, MD, John Barrett, MD, Minoo Battiwalla, MDMS

Blood (2014) 124 (21): 3898.

https://doi.org/10.1182/blood.V124.21.3898.3898

Published: 2014

Journal Articles

A Novel Standardized Quantitative Suppression Assay Reveals a Diversity of Human Immune-Regulatory Cell Potency

Samantha Miner, Nancy F. Hensel, Bahey Salem, Neil Dunavin, MD, Kazushi Tanimoto, MD, Minoo Battiwalla, MD MS, Kit Lu, MD, Keyvan Keyvanfar, BS, Marianna Sabatino, David Stroncek, Patrick J Hanley, PhD, Catherine M. Bollard, MBChB, MD, Katayoun Rezvani, MD, PhD, Marcin Kortylewski, PhD, Pawel Muranski, MD, John Barrett, MD, Sawa Ito, MD

Blood (2014) 124 (21): 316.

https://doi.org/10.1182/blood.V124.21.316.316

Published: 2014

Journal Articles

Ex Vivo Generation of CD4 + Th17 Cells to Prevent and Treat Infection from Antibiotic-Resistant Klebsiella Pneumoniae in Immunocompromised Patients

Pawel Muranski, MD, Manuel Franco-Colon, Dhanalakshmi Chinnasamy, Kong Chen, Scott Stegemann, Jinwen Sui, Sawa Ito, MD, Marianna Sabatino, MD, David F. Stroncek, MD, Tara Palmore, Jay Kolls, A John Barrett, MD

Blood (2014) 124 (21): 2445.

https://doi.org/10.1182/blood.V124.21.2445.2445

Published: 2014

Journal Articles

Phase 1 Trial Of Bone Marrow Stromal Cells (Bone Marrow-derived MSCS) To Treat Tissue Damage In Allogeneic Stem Cell Transplant Recipients: Biological Markers Correlate With Clinical Responses and Survival

Minoo Battiwalla, MD, MS, Fang Yin, MD, Sawa Ito, Xingmin Feng, PhD, Fariba Chinian, M.S., J. Joseph Melenhorst, PhD, Eleftheria K Koklanaris, BSN, Marianna Sabatino, David Stroncek, MD, Leigh Samsel, MS, Jeffrey K. Klotz, MD, Nancy F. Hensel, Pamela Robey, PhD, A. John Barrett, MD

Blood (2013) 122 (21): 3282.

https://doi.org/10.1182/blood.V122.21.3282.3282

Published: 2013

Journal Articles

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Daniel W. Lee, III, MD, Nirali N Shah, MD, Maryalice Stetler-Stevenson, MD, PhD, Marianna Sabatino, Cindy Delbrook, RN, Kelly Richards, RN, James N Kochenderfer, M.D., Steven A. Rosenberg, M.D., Ph.D., David Stroncek, MD, Alan S. Wayne, MD, Crystal L Mackall, MD

Blood (2013) 122 (21): 68.

https://doi.org/10.1182/blood.V122.21.68.68

Published: 2013

Journal Articles

Ex Vivo Generation Of CD4 + T Cells To Prevent and Treat Infection From Antibiotic-Resistant Klebsiella Pneumoniae In Immunocompromised Patients

Manuel Franco-Colon, Kong Chen, Dhanalakshmi Chinnasamy, Marianna Sabatino, David Stroncek, MD, Sawa Ito, Tara Palmore, Jay Kolls, A. John Barrett, Pawel Muranski

Blood (2013) 122 (21): 2022.

https://doi.org/10.1182/blood.V122.21.2022.2022

Published: 2013

Journal Articles

Phase 2 clinical trial of rapamycin-resistant donor CD4 + Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

Blood (2013) 121 (15): 2864–2874.

https://doi.org/10.1182/blood-2012-08-446872

Published: 2013

Includes: Supplemental data

Journal Articles

Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT

Blood (2012) 120 (21): 471.

https://doi.org/10.1182/blood.V120.21.471.471

Published: 2012

Journal Articles

Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD, PhD, Marianna Sabatino, MD, Barbara Tumaini, MS, Kelly Richards, RN, Cindy Delbrook, RN, James N Kochenderfer, M.D., Steven A. Rosenberg, David Stroncek, MD, Crystal L Mackall, MD, Alan S Wayne, MD

Blood (2012) 120 (21): 2609.

https://doi.org/10.1182/blood.V120.21.2609.2609

Published: 2012

Journal Articles

4-Log Ex-Vivo T-Lymphocyte Depleted Myeloablative HLA-Matched Sibling Transplants; a Platform for Adoptive Immunotherapy

Minoo Battiwalla, MD, MS, Zachariah A. McIver, DO, Janice Haggerty, Eleftheria K. Koklanaris, BS, Kamna Chawla, MD, MS, Jeanine Superata, Richard Childs, MD, Roger Kurlander, MD, David Stroncek, MD, Hanh Khuu, Deborah Citrin, Marianna Sabatino, MD, Susan Leitman, MD, A. John Barrett, MD

Blood (2010) 116 (21): 2091.

https://doi.org/10.1182/blood.V116.21.2091.2091

Published: 2010

Journal Articles

T-Rapa Cell Clinical Products Contain a Balance of Minimally Differentiated Th2/Th1 Effector Cells Depleted of Treg Cells

Miriam E. Mossoba, PhD, Jacopo Mariotti, MD, Xiao-Yi Yan, Anu Gangopadhyay, Mathew Winterton, Marianna Sabatino, MD, Hanh Khuu, MD, Vicki Fellowes, Frances T. Hakim, PhD, David Stroncek, MD, Susan Leitman, MD, Bruce L Levine, PhD, Carl H. June, MD, Daniel H Fowler, MD

Blood (2010) 116 (21): 352.

https://doi.org/10.1182/blood.V116.21.352.352

Published: 2010

Journal Articles

Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy

Blood (2010) 116 (21): 521.

https://doi.org/10.1182/blood.V116.21.521.521

Published: 2010

NARROW

Very Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy for Prevention of Viral Infection after Allogeneic T Cell Depleted Stem Cell Transplantation

Production of Anti-CD19 CAR T Cells for ZUMA-3 and -4: Phase 1/2 Multicenter Studies Evaluating KTE-C19 in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL)

Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy to Prevent Viral Reactivation in Recipients of Allogeneic T Cell Depleted Stem Cell Transplant

Generation of clinical-grade CD19-specific CAR-modified CD8 + memory stem cells for the treatment of human B-cell malignancies

Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation

A Novel Standardized Quantitative Suppression Assay Reveals a Diversity of Human Immune-Regulatory Cell Potency

Ex Vivo Generation of CD4 + Th17 Cells to Prevent and Treat Infection from Antibiotic-Resistant Klebsiella Pneumoniae in Immunocompromised Patients

Phase 1 Trial Of Bone Marrow Stromal Cells (Bone Marrow-derived MSCS) To Treat Tissue Damage In Allogeneic Stem Cell Transplant Recipients: Biological Markers Correlate With Clinical Responses and Survival

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Ex Vivo Generation Of CD4 + T Cells To Prevent and Treat Infection From Antibiotic-Resistant Klebsiella Pneumoniae In Immunocompromised Patients

Phase 2 clinical trial of rapamycin-resistant donor CD4 + Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT

Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

4-Log Ex-Vivo T-Lymphocyte Depleted Myeloablative HLA-Matched Sibling Transplants; a Platform for Adoptive Immunotherapy

T-Rapa Cell Clinical Products Contain a Balance of Minimally Differentiated Th2/Th1 Effector Cells Depleted of Treg Cells

Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only